PMS-RISEDRONATE PLUS CALCIUM TABLET

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE); CALCIUM (CALCIUM CARBONATE)

Disponibbli minn:

PHARMASCIENCE INC

Kodiċi ATC:

M05BB02

INN (Isem Internazzjonali):

RISEDRONIC ACID AND CALCIUM, SEQUENTIAL

Dożaġġ:

35MG; 500MG

Għamla farmaċewtika:

TABLET

Kompożizzjoni:

RISEDRONATE SODIUM (RISEDRONATE SODIUM HEMIPENTAHYDRATE) 35MG; CALCIUM (CALCIUM CARBONATE) 500MG

Rotta amministrattiva:

ORAL

Unitajiet fil-pakkett:

100

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

BONE RESORPTION INHIBITORS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0251633001; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2011-02-17

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
PR PMS-RISEDRONATE PLUS CALCIUM
Risedronate Sodium (as the hemi-pentahydrate) 35 mg Tablets, House
Standard
BONE METABOLISM REGULATOR
and
Calcium Carbonate 1250 mg Caplets, House Standard
(Equivalent to 500 mg elemental calcium)
MINERAL SUPPLEMENT
PHARMASCIENCE INC.
DATE OF REVISION:
6111 Royalmount Avenue, Suite 100,
June 08, 2016
Montreal QC, H4P 2T4
www.pharmascience.com
Control Number: 195294
_ _
_pms-RISEDRONATE PLUS CALCIUM - Product Monograph Page 2 of 38_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.............................................................. 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
5
ADVERSE
REACTIONS...........................................................................................................
7
DRUG INTERACTIONS
.........................................................................................................
10
DOSAGE AND ADMINISTRATION
.....................................................................................
13
OVERDOSAGE
.......................................................................................................................
15
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 15
STORAGE AND STABILITY
.................................................................................................
19
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 20
PART II: SCIENTIFIC INFORMATION
....................................................................................
21
PHARMACEUTICAL
INFORMA